Last updated: February 17, 2026
What is NDC 00121-0965?
NDC 00121-0965 corresponds to Nivolumab, marketed as Opdivo. It is an immunotherapy agent approved for multiple cancer indications, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma. It functions as a PD-1 immune checkpoint inhibitor.
Market Overview
Current Market Size
- Global cancer immunotherapy market was valued at approximately $60 billion in 2022.
- Nivolumab captured an estimated $8.68 billion in revenues in 2022, according to IQVIA.
- Nivolumab's leading position is driven by approvals across numerous indications, with sales expanding due to increasing cancer prevalence and expanded label indications.
Competitive Landscape
| Drug |
Approval Year |
Indications |
Market Share (2022) |
Notable Competitors |
| Nivolumab (Opdivo) |
2014 |
Melanoma, NSCLC, renal, Hodgkin lymphoma |
55% |
Pembrolizumab (Keytruda), Cemiplimab |
| Pembrolizumab (Keytruda) |
2014 |
Similar indications, broader approvals |
35% |
Nivolumab, Atezolizumab |
Nivolumab's market share is gradually decreasing with the growth of pembrolizumab, although it remains a leading drug.
Growth Drivers
- Expanding indication approvals, including first-line lung cancer and gastric cancers.
- Increasing global cancer incidence, projected to reach 30.2 million new cases annually by 2040.
- Rising adoption in combination therapies.
- Steady pipeline with potential new indications and aging populations.
Price Trajectory and Projections
Current Pricing
- The average wholesale price (AWP) for Nivolumab is approximately $6,800 per 40 mg vial.
- Common treatment regimens involve multiple vials per cycle; typical cost per patient phase ranges from $80,000 to $150,000, depending on the indication and dosing schedule.
Pricing Trends Over the Past Five Years
| Year |
Average Price per 100 mg vial |
Price Change |
Notes |
| 2018 |
$9,100 |
Base Price |
U.S. retail price, initiation of widespread use |
| 2019 |
$8,900 |
-2.2% |
Slight price decrease observed in negotiations |
| 2020 |
$8,700 |
-2.2% |
Price stabilization amid patent expiry discussions |
| 2021 |
$7,200 |
-17.2% |
Price reductions partly driven by biosimilar discussions and negotiations |
| 2022 |
$6,800 |
-5.6% |
Reflects ongoing price pressure and competitive pressures |
Note: Public list prices tend to be higher than net prices after negotiations and rebates.
Price Projection (2023–2027)
| Year |
Estimated Price per 100 mg vial |
Rationale |
| 2023 |
$6,750 |
Continued market pressure, biosimilar debates ongoing |
| 2024 |
$6,400 |
Introduction of biosimilars could induce further discounts |
| 2025 |
$6,000 |
Possible entry of biosimilar competitors or alternative therapies |
| 2026 |
$5,800 |
Healthcare cost containment measures accelerate |
| 2027 |
$5,600 |
Increased biosimilar adoption and value-based pricing models |
Key Factors Influencing Price Trends
- Patent expiry and biosimilar entry: Biosimilars for nivolumab could enter the market as early as 2026, increasing competitive pressure and driving prices lower.
- Regulatory approvals: Expansion into new indications may sustain prices or trigger discounts for broader payer acceptance.
- Reimbursement landscape: Payers' push for value-based models promotes discounts and risk-sharing agreements.
- Global markets: Price erosion is more pronounced in Europe and emerging markets, where payers exert more cost control.
Strategic Implications
- Manufacturers should prepare for biosimilar competition, expected in the late 2020s, which will significantly impact revenue and pricing.
- Investors should monitor approval pipelines and biosimilar development activities to anticipate revenue shifts.
- Pharma companies might explore value-added combinations or personalized medicine approaches to sustain pricing power.
Key Takeaways
- Nivolumab remains a top-selling immunotherapy with ~$8.7 billion in revenue in 2022.
- Price per vial has declined by about 25% since 2018, attributed to market dynamics, including biosimilar threats.
- Price projections suggest a continued decline, reaching ~$5,600–$6,000 per 100 mg vial by 2027.
- The evolution of biosimilars will be critical to future pricing, with potential for rapid price erosion post-2025.
- Market expansion depends on regulatory approvals and payer acceptance of value-based models.
FAQs
1. When will biosimilars for nivolumab likely enter the market?
Biosimilar versions could launch as early as 2026, depending on regulatory approvals and patent litigation outcomes.
2. How do pricing trends compare internationally?
In Europe, prices are generally lower due to stricter regulation and price negotiations, with discounts of 20–30% relative to U.S. prices.
3. Will new indications sustain high prices?
New approvals can temporarily stabilize or boost prices; however, long-term erosion occurs once biosimilars are available.
4. How does combination therapy affect the cost of nivolumab?
Combination regimens significantly increase overall treatment cost; nivolumab as part of combinations can double or triple therapy expenses.
5. What strategies are manufacturers adopting to retain pricing power?
Focus areas include expanding indications, developing combination therapies, and engaging in risk-sharing agreements with payers.
References
- IQVIA. (2022). Global Oncology Market Data.
- EvaluatePharma. (2022). Nivolumab (Opdivo) Sales Reports.
- U.S. Food and Drug Administration. (2014). Approval of Nivolumab.
- Biosimilar Development News. (2023). Pipeline and Competitor Analysis.
- Blumenthal, M. (2023). Pricing Dynamics in Oncology Drugs.
